Targeting oxidative stress in heart failure

Heart and Metabolism

Volumn , Issue 42, 2009, Pages 21-24

  Ng, Leong L ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Heart failure; Oxidative stress; Therapeutics

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ANTIOXIDANT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDAVARONE; GAMMA TOCOPHEROL; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEBIVOLOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC ACID DERIVATIVE; OXIPURINOL; PROBUCOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOL; ROSUVASTATIN; UBIQUINONE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ARTICLE; CLINICAL TRIAL; DNA CLEAVAGE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; HEART FAILURE; HEART HYPERTROPHY; HEART VENTRICLE FUNCTION; HUMAN; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 64849115307     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993;14:1493-1498.
2. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:245-248.
3. Ide T, Tsutsui H, Kinugawa S, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. ̂ Res. 2000;86:1 52-157.
4. Dieterich S, Bieligk U, Beulich K, Hasenfuss G, PrestleJ. Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart. & Circulation. 2000;101:33-39.
5. Sam F, Kerstetter DL, Pimental DR, et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005;11:473-480.
6. Ide T, Tsutsui H, Kinugawa S, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357-363.
7. Tang WH, Brennan ML, Philip K, et al. Plasma myeloperoxidase levels in patients with chronic heartfailure. Am J Cardiol. 2006;98:796-799.
8. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2006;152:94-101.
9. Matsuzawa A, Nishitoh H, Tobiume K, Takeda K, Ichijo H. Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signal. 2002;4:41 5-425.
10. Hirotani S, Otsu K, Nishida K, et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G- protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 2002;105:509-51 5.
11. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability, J Clin Invest. 1996;98:2572-2579.
12. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280:C53- C60.
13. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metal loproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ. Res. 2001;89: 201-210.
14. Koh DW, Dawson TM, Dawson VL. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res. 2005;52:5-14.
15. Remondino A, Kwon SH, Communal C, et al. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ. Res. 2003;92:136-138.
16. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25: 731-741.
17. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67:1097-1107.
18. Mühlhäuser U, ZoIk O, Rau T, Münzel F, Wieland T, Eschenhagen T. Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB J. 2006;20:785-787.
19. Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002;53:911-920.
20. Kjekshus J, Apetrei E, Barrios V, et al., for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.
21. Taylor AL, ZiescheS, Yancy C, etal., for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrateand hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
22. Daiber A, Oelze M, Coldewey M, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865-1874.
23. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004;110:21 75-21 79.
24. Hare JM, Mangal B, Brown J, et al., for the OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301-2309.
25. Sander S, Coleman Cl, Patel AA, Kluger J, White CM. The impact of coenzyme QI0 on systolic function in patients with chronic heart failure. J Card Fail. 2006; 12:464-472.
26. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and endpoints of "Q-symbio" - a multinational trial. Biofactors. 2003;1 8:79-89.
27. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1 996;334:1145-1149.
28. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:1 54-1 60.
29. Nakamura R, Egashira K, Machida Y, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation. 2002;106:362-367.
30. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents Cardiovasc Drug Discov. 2006;1:85-93.